Logo image of FBIO

FORTRESS BIOTECH INC (FBIO) Stock Fundamental Analysis

NASDAQ:FBIO - Nasdaq - US34960Q3074 - Common Stock - Currency: USD

1.78  +0.05 (+2.89%)

After market: 1.73 -0.05 (-2.81%)

Fundamental Rating

2

FBIO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 562 industry peers in the Biotechnology industry. FBIO has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, FBIO is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

FBIO had negative earnings in the past year.
FBIO had a negative operating cash flow in the past year.
In the past 5 years FBIO always reported negative net income.
FBIO had a negative operating cash flow in each of the past 5 years.
FBIO Yearly Net Income VS EBIT VS OCF VS FCFFBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

Looking at the Return On Assets, with a value of -38.75%, FBIO is in line with its industry, outperforming 56.51% of the companies in the same industry.
FBIO has a Return On Equity of -245.82%. This is in the lower half of the industry: FBIO underperforms 71.66% of its industry peers.
Industry RankSector Rank
ROA -38.75%
ROE -245.82%
ROIC N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
FBIO Yearly ROA, ROE, ROICFBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

1.3 Margins

Looking at the Gross Margin, with a value of 63.80%, FBIO is in the better half of the industry, outperforming 79.14% of the companies in the same industry.
FBIO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for FBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 63.8%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
FBIO Yearly Profit, Operating, Gross MarginsFBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

1

2. Health

2.1 Basic Checks

FBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
FBIO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, FBIO has more shares outstanding
Compared to 1 year ago, FBIO has a worse debt to assets ratio.
FBIO Yearly Shares OutstandingFBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
FBIO Yearly Total Debt VS Total AssetsFBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -8.92, we must say that FBIO is in the distress zone and has some risk of bankruptcy.
FBIO's Altman-Z score of -8.92 is on the low side compared to the rest of the industry. FBIO is outperformed by 72.01% of its industry peers.
A Debt/Equity ratio of 2.55 is on the high side and indicates that FBIO has dependencies on debt financing.
FBIO has a worse Debt to Equity ratio (2.55) than 82.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.55
Debt/FCF N/A
Altman-Z -8.92
ROIC/WACCN/A
WACC11.94%
FBIO Yearly LT Debt VS Equity VS FCFFBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M -150M

2.3 Liquidity

FBIO has a Current Ratio of 1.27. This is a normal value and indicates that FBIO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.27, FBIO is doing worse than 84.85% of the companies in the same industry.
FBIO has a Quick Ratio of 1.06. This is a normal value and indicates that FBIO is financially healthy and should not expect problems in meeting its short term obligations.
FBIO has a worse Quick ratio (1.06) than 86.81% of its industry peers.
Industry RankSector Rank
Current Ratio 1.27
Quick Ratio 1.06
FBIO Yearly Current Assets VS Current LiabilitesFBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

6

3. Growth

3.1 Past

FBIO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 63.55%, which is quite impressive.
Looking at the last year, FBIO shows a very negative growth in Revenue. The Revenue has decreased by -31.76% in the last year.
The Revenue has been growing by 9.50% on average over the past years. This is quite good.
EPS 1Y (TTM)63.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.41%
Revenue 1Y (TTM)-31.76%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%-24.2%

3.2 Future

The Earnings Per Share is expected to grow by 22.90% on average over the next years. This is a very strong growth
Based on estimates for the next years, FBIO will show a very strong growth in Revenue. The Revenue will grow by 64.44% on average per year.
EPS Next Y49.88%
EPS Next 2Y29.87%
EPS Next 3Y22.9%
EPS Next 5YN/A
Revenue Next Year56.79%
Revenue Next 2Y61.67%
Revenue Next 3Y50.04%
Revenue Next 5Y64.44%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FBIO Yearly Revenue VS EstimatesFBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M
FBIO Yearly EPS VS EstimatesFBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FBIO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FBIO Price Earnings VS Forward Price EarningsFBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FBIO Per share dataFBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

A more expensive valuation may be justified as FBIO's earnings are expected to grow with 22.90% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y29.87%
EPS Next 3Y22.9%

More info and screens

0

5. Dividend

5.1 Amount

FBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

FORTRESS BIOTECH INC

NASDAQ:FBIO (5/23/2025, 9:31:43 PM)

After market: 1.73 -0.05 (-2.81%)

1.78

+0.05 (+2.89%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-15 2025-05-15/amc
Earnings (Next)08-11 2025-08-11/amc
Inst Owners17.31%
Inst Owner Change2.7%
Ins Owners20.71%
Ins Owner Change26.76%
Market Cap52.63M
Analysts82.22
Price Target15.64 (778.65%)
Short Float %15.8%
Short Ratio14.32
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.22
Dividend Growth(5Y)-17.74%
DP-8.43%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-11.42%
Min EPS beat(2)-25.23%
Max EPS beat(2)2.39%
EPS beat(4)3
Avg EPS beat(4)15.07%
Min EPS beat(4)-25.23%
Max EPS beat(4)41.63%
EPS beat(8)5
Avg EPS beat(8)20.17%
EPS beat(12)7
Avg EPS beat(12)13.83%
EPS beat(16)8
Avg EPS beat(16)-21.32%
Revenue beat(2)0
Avg Revenue beat(2)-32.26%
Min Revenue beat(2)-55.48%
Max Revenue beat(2)-9.04%
Revenue beat(4)0
Avg Revenue beat(4)-18.82%
Min Revenue beat(4)-55.48%
Max Revenue beat(4)-1.14%
Revenue beat(8)3
Avg Revenue beat(8)8.65%
Revenue beat(12)4
Avg Revenue beat(12)1.11%
Revenue beat(16)6
Avg Revenue beat(16)-2.1%
PT rev (1m)0%
PT rev (3m)2.22%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-312.5%
EPS NY rev (1m)0%
EPS NY rev (3m)-8.32%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-47.75%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-31.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.91
P/FCF N/A
P/OCF N/A
P/B 2.31
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-3.27
EYN/A
EPS(NY)-1.64
Fwd EYN/A
FCF(TTM)-3.22
FCFYN/A
OCF(TTM)-2.71
OCFYN/A
SpS1.95
BVpS0.77
TBVpS-0.31
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -38.75%
ROE -245.82%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 63.8%
FCFM N/A
ROA(3y)-36.39%
ROA(5y)-27.89%
ROE(3y)-252.68%
ROE(5y)-172.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y6.13%
GM growth 5Y-2.19%
F-Score1
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity 2.55
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 336.02%
Cap/Sales 26.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.27
Quick Ratio 1.06
Altman-Z -8.92
F-Score1
WACC11.94%
ROIC/WACCN/A
Cap/Depr(3y)152.42%
Cap/Depr(5y)127.86%
Cap/Sales(3y)11.86%
Cap/Sales(5y)9.94%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)63.55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.41%
EPS Next Y49.88%
EPS Next 2Y29.87%
EPS Next 3Y22.9%
EPS Next 5YN/A
Revenue 1Y (TTM)-31.76%
Revenue growth 3Y-5.71%
Revenue growth 5Y9.5%
Sales Q2Q%-24.2%
Revenue Next Year56.79%
Revenue Next 2Y61.67%
Revenue Next 3Y50.04%
Revenue Next 5Y64.44%
EBIT growth 1Y20.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year62.35%
EBIT Next 3Y22.94%
EBIT Next 5YN/A
FCF growth 1Y28.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y37.46%
OCF growth 3YN/A
OCF growth 5YN/A